CDXC צמיחת הכנסות מרבעון לרבעון ChromaDex Corp.

Rob Fried's strategic control and strong management drive the expansion of patented components for ChromaDex Corporation (CDXC). Line automation and AI-driven formulation control at plants reduce costs, while the quarterly revenue growth trajectory confirms business resilience, where the 37.90 mark indicates the yield level. Leading cellular senescence scientists, developing innovative longevity formulas in state-of-the-art laboratories, sustain this stability.
פילוחים אנליטיים ודוחות נתונים של חברת chromadex.com (CDXC)

ChromaDex Corporation (CDXC) leadership in the NAD+ segment and its Niagen patents drive the company's commercial success through demand for cellular regeneration. Quarterly sales dynamics measure the percentage change in revenue over three months, allowing investors to assess operational resilience and the risk of business overheating by analyzing the current level of quarterly sales growth.